Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis.

Abdullah Salah Alanazi Ismaeel Yunusa Khaled Elenizi Abdulaziz Ibrahim Alzarea

Published in: Lung cancer management (2020)

In this NMA, we found that osimertinib is the most efficacious and safest EGFR-TKI. These results may guide clinicians in choosing the most appropriate treatment option among EGFR-TKIs for their patient's individual clinical characteristics.

Keyphrases

epidermal growth factor receptor
advanced non small cell lung cancer
tyrosine kinase
case report
palliative care
small cell lung cancer
combination therapy